NANCY DENYES - 05 Jan 2024 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
General Counsel
Signature
/s/ Nancy E. Denyes
Issuer symbol
LIFE
Transactions as of
05 Jan 2024
Transactions value $
$0
Form type
4
Filing time
09 Jan 2024, 19:30:22 UTC
Previous filing
21 Feb 2023
Next filing
06 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LIFE Common Stock 12,079 05 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Employee Stock Option (right to buy) Award $0 +150,000 $0 150,000 05 Jan 2024 Common Stock 150,000 $1.5 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,500 shares acquired on May 15, 2023 and 2,500 shares acquired on November 15, 2023 under the Company's 2015 Employee Stock Purchase Plan.
F2 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.